Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland
Open Access
- 1 May 2021
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (5) , 671-672
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Beating the odds with systematic individualized care: Nationwide prospective follow‐up of all patients with COVID‐19 in IcelandJournal of Internal Medicine, 2020
- Spread of SARS-CoV-2 in the Icelandic PopulationNew England Journal of Medicine, 2020
- Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative dataJournal of Advanced Research, 2019
- Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysisThe Lancet, 2015